Collectively, these findings indicate that TKT overexpression promotes cisplatin resistance, whereas knockdown of either TKT or PKM2 enhances RCC cell sensitivity to cisplatin, supporting the involvement of the TKT-PKM2 axis in regulating the cisplatin response in RCC. The gene discussed is PKM; the disease is renal cell carcinoma.